Loading...
Loading...
SAGE Therapeutics
SAGE today announced it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the STATUS Trial (SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus), a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate SAGE-547 as a treatment for patients with super-refractory status epilepticus (SRSE). The SPA provides agreement from the FDA that the Phase 3 STATUS Trial can adequately address objectives in support of a U.S. regulatory submission for approval of SAGE-547 for the treatment of patients with SRSE. SRSE is a rare, life-threatening condition of persistent, unremitting seizure, for which there are no approved therapies.
"This is a major accomplishment for SAGE Therapeutics. By obtaining FDA agreement on the Phase 3 STATUS Trial design, endpoints, patient population and statistical approach, we have a clear path on moving forward with our development and regulatory plan for SAGE-547 in SRSE. As first movers in seeking a treatment for this life-threatening disorder, we believe our SPA is an important mechanism to further de-risk our development pathway. We look forward to enrolling patients in the Phase 3 STATUS Trial imminently," said
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in